Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best multibagger stocks to invest in right now. The company’s focus lies on its lead asset, Seralutinib, which targets pulmonary arterial hypertension (PAH), a severe condition with limited treatment options. Investor enthusiasm for the stock has grown markedly this year. It was trading around $1 at the start of the year and has since climbed to $2.50, delivering nearly 180% returns year-to-date.

Pressmaster/Shutterstock.com

In line with that performance, analyst sentiment has also strengthened. Gossamer Bio Inc. received a Buy rating from Yasmeen Rahimi of Piper Sandler on September 5, with a price target of $15 reiterated.

The call comes shortly after H.C. Wainwright’s Patrick Trucchio reaffirmed his Buy rating on August 19 with a $10 target, highlighting confidence in the company’s lead candidate, seralutinib.

Trucchio’s report highlighted that the recent literature reviews and trial extensions have reinforced optimism around seralutinib. Data from the open-label extension of the Phase 2 study showed benefits held-up for 72 weeks, including reduced pulmonary vascular resistance and improved six-minute walk distance. These findings suggest the drug may have disease-modifying potential rather than offering only short-term relief.

He also pointed to the possibility of using seralutinib in combination with other therapies, which could broaden its role in pulmonary treatment. The upcoming Phase 3 PROSERA trial, with results expected in February 2026, remains the next major catalyst.

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company developing therapies for pulmonary and cardiovascular diseases.

READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.

This article is originally published at Insider Monkey.